Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 235
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
Save to Existing Project
Save to a New Project
Enzyme of Having Degradation Function About Dental Plaque_LeeonIPL
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
This technology relates to DXAMase purified from a strain of Lipomyces starkeyi KSM22...
Contact Mikyeong Lee
Email me a copy of this message
Dental plaque consists of 70% mocroorganisms and 30% insoluble glucan/DXAMase of this technology has a function of suppresing plaque formation by degrading insoluble glucan into water-soluble glucose

This technology relates to DXAMase purified from a strain of Lipomyces starkeyi KSM22. Specifically, this technology revealed that the enzyme isolated from the Lipomyces starkeyi KSM22 strain shows high ability to degrade substrates related to plaque formation, such as mutan, dextran, starch, sugar and levan. The enzyme was named “DXAMase”.


o    DXAMase enzyme has high ability to degrade insoluble glucan, a major component of plaque, and thus can prevent tooth decay, tartar buildup, gingivitis, periodontitis, etc.


o    DXAMase was tested for toxicity in the Korea Research Institute of Chemical Technology, and the results thereof did not reveal any toxicity in terms of mortality, general symptoms, body weight change, or autopsy findings.

o    DXAMase is stable at pH 4.5~8 and -30~60 ? and showed a significantly improved synergistic effect when used in combination with existing products (chemicals).  Thus, DXAMase can be included in tooth-related products, such as mouthwash, toothpaste, milk powder, milk and gum for dental care.

o    Maximum prevention of plaque thickening, superior plaque degradation effect, minimization of spread of periodontitis, excellent adhesion to teeth, and maximization of synergistic effect with mouse rinse.

Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE

Opportunity Contact